Development asset linked to Alfasigma in public FDA and regional records.
pharma · Juvenile idiopathic arthritis · juvenile idiopathic arthritis
Alfasigma
Alfasigma S.p.A.
Alfasigma drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
BOLOGNA, IT HQ
2,481 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- BOLOGNA, IT
- Employees
- 2,481
- Programs
- 8
- Drugs
- 8
- Patents
- 25
Alfasigma pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Alfasigma drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Alfasigma in public FDA and regional records.
-
filgotinib
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Alfasigma's portfolio. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK3 inhibitor
-
Development asset linked to Alfasigma in public FDA and regional records. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
Development asset linked to Alfasigma in public FDA and regional records.
-
Development asset linked to Alfasigma in public FDA and regional records.
-
Development asset linked to Alfasigma in public FDA and regional records.
-
Development asset linked to Alfasigma in public FDA and regional records.